Premium
Canine acute leukaemia: 50 cases (1989–2014)
Author(s) -
Bennett A. L.,
Williams L. E.,
Ferguson M. W.,
Hauck M. L.,
Suter S. E.,
Lanier C. B.,
Hess P. R.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12251
Subject(s) - medicine , cytopenia , chemotherapy , malignancy , bone marrow , haematopoiesis , refractory (planetary science) , surgery , gastroenterology , stem cell , physics , biology , astrobiology , genetics
Abstract Acute leukaemia ( AL ) is a bone marrow malignancy of hematopoietic progenitors that historically is poorly responsive to treatment. With the widespread adoption of dose‐intense chemotherapy, more human patients attain long‐term survivals, but whether comparable progress has been made in canine AL is unknown. To investigate this question, medical records from three academic veterinary hospitals were reviewed. Fifty dogs met the criteria for AL , having excess circulating or marrow blasts, a major cytopenia(s), and no substantial lymphadenopathy. Thirty‐six dogs received cytotoxic chemotherapy; 23 achieved a complete or partial response for a median of 56 days (range, 9–218). With failure or relapse, 14 dogs were rescued. Median survival with treatment was poor at 55 days (range, 1–300). Untreated ( n = 6) and palliatively‐treated ( n = 8) dogs lived a median of 7.5 days. Most dogs developed chemoresistance within weeks of initiating treatment, and consequently, survival times for AL remain disappointingly short.